Christine A. Ciunci, MD MSCE
Associate Professor of Clinical Medicine (Hematology-Oncology)
Attending , Hospital of the University of Pennsylvania
Attending , Penn Presbyterian Medical Center
Physician Lead for the Cancer Service Line, Penn Presbyterian Medical Center
Physician Lead for PPMC Oncology Clinical Research Program , Penn Presbyterian Medical Center
Co-Director, Cancer Diagnostics Clinic, Hospital of University of Penn
Vice Chief for Clinical Affairs and Quality , Division of Hematology-Oncology, University of Pennsylvania
Department: Medicine
Contact information
Abramson Cancer Center
Penn Presbyterian Medical Center
Pavilion for Advanced Care, 1st Floor
51 N 39th Street
Philadelphia, PA 19104
Penn Presbyterian Medical Center
Pavilion for Advanced Care, 1st Floor
51 N 39th Street
Philadelphia, PA 19104
Office: 215-662-9801
Fax: 2152433249
Fax: 2152433249
Education:
BS (Biology)
Ursinus College, 2004.
MD (Medicine)
Temple University, 2008.
MSCE (MSCE)
University of Pennsylvania School of Medicine, 2014.
Permanent linkBS (Biology)
Ursinus College, 2004.
MD (Medicine)
Temple University, 2008.
MSCE (MSCE)
University of Pennsylvania School of Medicine, 2014.
Description of Clinical Expertise
thoracic malignancieslung cancer
occult primary
cancer diagnostics clinic
Description of Research Expertise
thoracic malignancieslung cancer
Selected Publications
Elghawy O, Barsouk A, Sussman JH, Bleiberg BA, Reed-Guy L, D'Avella C, Singh A, Ciunci C, Robinson K, Kosteva J, Langer C, Cohen RB, Aggarwal C, Marmarelis M, Sun L.: Late Immune-Related Adverse Events After At Least Two Years of Immune Checkpoint Inhibitor Therapy: Incidence and Association With Survival in Patients With Advanced NSCLC. JTO Clin Res Rep 6(9): 100851, May 2025.Elghawy O, Barsouk A, Reed-Guy L, Stalker M, Sussman J, Robinson K, Kosteva J, Singh A, Cohen RB, Langer C, Ciunci C, D'Avella C, Sun L, Marmarelis ME, Aggarwal C.: Brief Report: Osimertinib Plus Capmatinib for Patients With MET-Altered EGFR-Mutant NSCLC Following Progression on Front Line Therapy. Clin Lung Cancer 26(2): 158-163.e2. Mar 2025.
Barsouk A, Friedes C, Iocolano M, Doucette A, Cohen RB, Robinson KW, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Levin WP, Cengel KA, Bradley JD, Feigenberg SJ, Sun L, Aggarwal C, Langer CJ, Yegya-Raman N.: Plunging Into the PACIFIC: Outcomes of Patients With Unresectable KRAS-Mutated Non-Small Cell Lung Cancer Following Definitive Chemoradiation and Durvalumab Consolidation. Clin Lung Cancer 25(3): e161-e171. May 2024.
Cantor DJ, Davis C, Ciunci C, Aggarwal C, Evans T, Cohen RB, Bauml JM, Langer CJ.: Brief Report: Long-Term Follow-Up of Adjuvant Pembrolizumab After Locally Ablative Therapy for Oligometastatic NSCLC. JTO Clin Res Rep 5(6): 100667, Mar 2024.
Ugarte S, D'Avella C, Gabriel P, Ciunci C, Roy M, Schwartz A, Boyk K, Walker S, Tindall J, Dougherty D: The cancer diagnostic clinic: A rapid access clinic to improve outcomes for patients with a suspected cancer diagnosis. American Society of Clinical Oncology Quality Care Symposium, San Francisco, CA. Jan 2024 Notes: "poster presentation"
Friedes C, Yegya-Raman N, Zhang S, Iocolano M, Cohen RB, Aggarwal C, Thompson JC, Marmarelis ME, Levin WP, Cengel KA, Ciunci CA, Singh AP, D'Avella C, Davis CW, Langer CJ, Feigenberg SJ.: Patterns of Failure in Metastatic NSCLC Treated With First Line Pembrolizumab and Use of Local Therapy in Patients With Oligoprogression. Clin Lung Cancer 25(1): 50-60.e6. Jan 2024.
Davis D, Jarrar S, Ciunci C: Synchronous Primary Lung Cancers Containing Discrete Driver Mutations in a Never-Smoker: Case Report. Case Reports Oncology 16(1): 1384-1389, Nov 2023.
Tompkins WP, Hwang WT, Yang YX, Singh A, Ciunci C, D'Avella C, Aggarwal C, Cohen RB, Langer CJ, Mamtani R, Marmarelis ME.: Brief Report: Second-line treatment outcomes in patients with advanced NSCLC previously treated with first-line immunotherapy regimens. Clin Lung Cancer 24(6): 558-562.e2. Sep 2023.
Yegya-Raman N, Berman AT, Ciunci CA, Friedes C, Berlin E, Iocolano M, Wang X, Lai C, Levin WP, Cengel KA, O'Reilly SE, Cohen RB, Aggarwal C, Marmarelis ME, Singh AP, Sun L, Bradley JD, Plastaras JP, Simone CB 2nd, Langer CJ, Feigenberg SJ.: Phase 2 Trial of Consolidation Pembrolizumab After Proton Reirradiation for Thoracic Recurrences of Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys 119(23): 56-65, Aug 2023.
Yegya-Raman N, Friedes C, Sun L, Iocolano M, Kim KN, Doucette A, Cohen RB, Robinson KW, Levin WP, Cengel KA, Lally B, Agarwal M, D'Avella CA, Marmarelis ME, Kosteva JA, Singh AP, Ciunci CA, Aggarwal C, Berman AT, Langer CJ, Feigenberg SJ.: Utilization and Factors Precluding Receipt of Checkpoint Inhibitor Consolidation for Stage III NSCLC in a Large US Academic Health System. Clin Lung Cancer 24(5): 474-482. Jul 2023.